166 related articles for article (PubMed ID: 29269797)
1. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
Ragon BK; Mehta RS; Gulbis AM; Saliba RM; Chen J; Rondon G; Popat UR; Nieto Y; Oran B; Olson AL; Patel K; Hosing CM; Qazilbash MH; Shah N; Kebriaei P; Shpall EJ; Champlin RE; Alousi AM
Bone Marrow Transplant; 2018 Mar; 53(3):315-325. PubMed ID: 29269797
[TBL] [Abstract][Full Text] [Related]
2. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
3. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
[TBL] [Abstract][Full Text] [Related]
4. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
6. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
7. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
8. Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.
Rashidi A; DeFor TE; Holtan SG; Blazar BR; Weisdorf DJ; MacMillan ML
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2297-2302. PubMed ID: 31325587
[TBL] [Abstract][Full Text] [Related]
9. Pentostatin in steroid-refractory acute graft-versus-host disease.
Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
Jacobsohn DA; Gilman AL; Rademaker A; Browning B; Grimley M; Lehmann L; Nemecek ER; Thormann K; Schultz KR; Vogelsang GB
Blood; 2009 Nov; 114(20):4354-60. PubMed ID: 19745067
[TBL] [Abstract][Full Text] [Related]
12. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment.
Arai S; Margolis J; Zahurak M; Anders V; Vogelsang GB
Biol Blood Marrow Transplant; 2002; 8(3):155-60. PubMed ID: 11939605
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB
J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478
[TBL] [Abstract][Full Text] [Related]
16. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
17. Steroid treatment of acute graft-
Bacigalupo A; Milone G; Cupri A; Severino A; Fagioli F; Berger M; Santarone S; Chiusolo P; Sica S; Mammoliti S; Sorasio R; Massi D; Van Lint MT; Raiola AM; Gualandi F; Selleri C; Sormani MP; Signori A; Risitano A; Bonifazi F;
Haematologica; 2017 Dec; 102(12):2125-2133. PubMed ID: 28971905
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.
Cho BS; Lee SE; Song HH; Lee JH; Yahng SA; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1136-43. PubMed ID: 22261380
[TBL] [Abstract][Full Text] [Related]
19. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.
MacMillan ML; Robin M; Harris AC; DeFor TE; Martin PJ; Alousi A; Ho VT; Bolaños-Meade J; Ferrara JL; Jones R; Arora M; Blazar BR; Holtan SG; Jacobsohn D; Pasquini M; Socie G; Antin JH; Levine JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2015 Apr; 21(4):761-7. PubMed ID: 25585275
[TBL] [Abstract][Full Text] [Related]
20. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems.
MacMillan ML; Weisdorf DJ; Wagner JE; DeFor TE; Burns LJ; Ramsay NK; Davies SM; Blazar BR
Biol Blood Marrow Transplant; 2002; 8(7):387-94. PubMed ID: 12171485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]